KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Free Cash Flow (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Free Cash Flow for 16 consecutive years, with $188.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 246.69% year-over-year to $188.1 million, compared with a TTM value of $513.2 million through Dec 2025, up 1304.95%, and an annual FY2025 reading of $513.2 million, up 1304.95% over the prior year.
  • Free Cash Flow was $188.1 million for Q4 2025 at Alnylam Pharmaceuticals, down from $293.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $342.3 million in Q3 2023 and bottomed at -$252.8 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$31.5 million, with a median of -$98.0 million recorded in 2021.
  • The sharpest move saw Free Cash Flow tumbled 1063.74% in 2024, then soared 567.27% in 2025.
  • Year by year, Free Cash Flow stood at -$109.3 million in 2021, then rose by 20.58% to -$86.8 million in 2022, then soared by 115.33% to $13.3 million in 2023, then crashed by 1063.74% to -$128.2 million in 2024, then soared by 246.69% to $188.1 million in 2025.
  • Business Quant data shows Free Cash Flow for ALNY at $188.1 million in Q4 2025, $293.8 million in Q3 2025, and $153.3 million in Q2 2025.